US Royalty Pharma strikes deal with PureTech Health on KarXT royalties
PureTech Health
161.60p
14:00 18/11/24
US-listed Royalty Pharma has acquired an interest in PureTech Health's royalty in Karuna Therapeutics' KarXT drug for up to $500m, with $100m in cash up front and up to $400m in additional payments contingent on the achievement of certain regulatory and commercial milestones.
FTSE 250
20,339.38
14:15 18/11/24
FTSE 350
4,451.78
14:15 18/11/24
FTSE All-Share
4,409.75
14:15 18/11/24
Pharmaceuticals & Biotechnology
19,119.62
14:15 18/11/24
As part of the deal, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on sales up to $2bn a year, after which threshold Royalty Pharma will receive 33% and PureTech will retain 67% of the royalty payments.
PureTech retains its 3.1% equity ownership in Karuna. Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals and 20% of sublicense income.
KarXT was invented by a team at PureTech, and is an oral treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer's disease. Karuna has announced that it plans to submit a New Drug Application for KarXT in schizophrenia to the US Food and Drug Administration in mid-2023.
Reporting by Frank Prenesti for Sharecast.com